1. Home
  2. NATH vs ENGN Comparison

NATH vs ENGN Comparison

Compare NATH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nathan's Famous Inc.

NATH

Nathan's Famous Inc.

N/A

Current Price

$98.00

Market Cap

413.9M

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.88

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NATH
ENGN
Founded
1916
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
413.9M
117.2M
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
NATH
ENGN
Price
$98.00
$1.88
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
17.0K
697.3K
Earning Date
06-09-2026
06-11-2026
Dividend Yield
1.99%
N/A
EPS Growth
N/A
56.85
EPS
2.14
N/A
Revenue
$104,201,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$45.78
N/A
Revenue Growth
7.81
N/A
52 Week Low
$88.67
$1.40
52 Week High
$113.59
$12.25

Technical Indicators

Market Signals
Indicator
NATH
ENGN
Relative Strength Index (RSI) 52.10 52.82
Support Level $97.73 $1.67
Resistance Level $99.02 $1.96
Average True Range (ATR) 0.83 0.08
MACD 0.08 0.00
Stochastic Oscillator 71.58 57.89

Price Performance

Historical Comparison
NATH
ENGN

About NATH Nathan's Famous Inc.

Nathan's Famous Inc is a branded licensor, wholesaler and retailer of products marketed under its brand. Its products are currently marketed for sale in thousands of locations, including supermarkets, mass merchandisers and club stores, selected foodservice locations and its company-owned and franchised restaurants throughout the United States and in twenty foreign countries. It considers itself to be in the foodservice industry. It has three segments Branded Product Program, Product Licensing, Restaurant Operations, of which majority of revenue is from Branded Product Program which derives from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors. It generates majority of revenue from United States.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: